Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fulgent Genetics, Inc. - Common Stock (NQ:FLGT)

19.68 +0.08 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Fulgent Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating EchoStar, Semler, ADTRAN, and Fulgent and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm
From Schall Law Firm
Via Business Wire
FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT
From Pomerantz LLP
Via GlobeNewswire
Fulgent Reports First Quarter 2025 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Third Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Participate in Upcoming Conferences
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Reports Second Quarter 2024 Financial Results
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
From Fulgent Genetics, Inc.
Via Business Wire
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
From Fulgent Pharma
Via Business Wire
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
From Fulgent Pharma
Via Business Wire
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
From Fulgent Pharma
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.